The content on this site is intended for healthcare professionals only
Dr Santiago Escrivá-de-Romani speaks to ecancer about the primary results from a phase 2a study of zanidatamab, palbociclib and fulvestrant in HER2+/HR+ metastatic breast cancer (mBC).
Dr Escrivá-de-Romani says that a previous analysis of the current single-arm, phase 2a study demonstrated antitumour activity and a tolerable safety profile for zanidatamab, palbociclib and fulvestrant in heavily pretreated patients with HER2+/HR+ mBC.
This study aimed to report the primary endpoint of progression-free survival at 6 months and other endpoints.
The results of this study support the further development of a novel chemotherapy-free treatment regimen for heavily pretreated patients with HER2+/HR+ mBC. This treatment regimen showed promising progression-free survival at 6 months and median progression-free survival with durable responses.
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
One-year mortality in older adults with breast cancer: prediction using different geriatric tools
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer
ASCO 2023: Breast cancer research highlights
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
